ResMed Q3 2026 Financial Results: Key Highlights and Investor Insights

Overview

ResMed Inc. (NYSE: RMD), a global leader in digital health and medical devices for sleep and respiratory care, has released its financial results for the third quarter ended March 31, 2026. The report provides comprehensive insight into the company’s financial performance, operational highlights, and capital structure, offering essential information for shareholders and potential investors.

Key Financial Highlights

• Net Revenue and Profitability:
  • Net income for Q3 2026 was \$398.7 million, up from \$365.0 million in the prior year period.
  • For the nine months ended March 31, 2026, net income totaled \$1.14 billion, compared to \$1.02 billion for the same period last year.
• Earnings Per Share (EPS):
  • Basic EPS for Q3 2026: \$2.74 (compared to \$2.49 in Q3 2025).
  • Diluted EPS for Q3 2026: \$2.74 (compared to \$2.48 in Q3 2025).
  • For the nine months, basic EPS was \$7.82 (vs. \$6.96 in the prior year), with diluted EPS at \$7.79 (vs. \$6.93 in the prior year).
• Revenue and Operating Income:
  • Operating income for Q3 2026: \$499.8 million (up from \$426.3 million in Q3 2025).
  • Operating income for the nine months: \$1.44 billion (compared to \$1.23 billion in the prior year).
• Total Assets and Equity:
  • Total assets as of March 31, 2026: \$8.78 billion (up from \$8.17 billion as of June 30, 2025).
  • Total stockholders’ equity: \$6.49 billion (up from \$5.67 billion as of June 30, 2025).

Share Capital and Dividends

• Outstanding shares as of April 27, 2026: 145,056,384 (excluding 45,826,079 treasury shares).
• Dividend declared per share for Q3 2026: \$0.60 (compared to \$0.53 in Q3 2025).
• For the nine months, total dividends per share declared: \$1.80 (vs. \$1.59 in the prior year).

Other Noteworthy Items

• Restructuring Charges: The company reported \$21.7 million in restructuring charges for the current quarter, reflecting strategic changes that may impact future profitability and cost structure.
• Treasury Stock: The firm holds a significant amount of treasury stock (45.8 million shares), which may be relevant for future buybacks or capital management initiatives.
• Comprehensive Income: Comprehensive income for Q3 2026 was \$203.7 million (impacted by significant unrealized losses on hedging instruments and foreign currency translation adjustments).
• Operating Expenses: Operating expenses totaled \$340.1 million for the quarter, up slightly from the prior year, in line with higher revenues and continued investment in R&D and SG&A.
• Interest and Investment Results:
  • Net interest income increased, with \$12.3 million in Q3 2026, versus \$0.8 million in the prior year.
  • The company booked losses on equity securities (unrealized mark-to-market losses), totaling \$10.1 million for the quarter and \$16 million for the nine months, which could indicate volatility in non-core investments.
• Hedging and Currency Effects: Large unrealized losses on designated hedging instruments (\$23.7 million for the quarter) and substantial foreign currency translation gains (\$58.3 million) affected comprehensive income. These could impact future financial results, especially given ResMed’s global footprint.

Capital Structure and Liquidity

• Common Stock: 190.9 million shares issued, with 145.0 million outstanding as of March 31, 2026.
• No Preferred Stock Issued: 2 million shares authorized but none issued.
• Strong Equity Base: The company’s equity position improved by over \$800 million in the past nine months, reflecting robust profitability and retained earnings growth.

Price-Sensitive Information & Potential Share Price Impacts

• Profit Growth: Strong net income and EPS growth are likely to be positively received by investors.
• Dividend Increase: The increase in dividend per share signals confidence in future cash flows and may attract yield-focused investors.
• Restructuring Charges: The recognition of \$21.7 million in restructuring expenses may indicate significant operational changes, which could be viewed as either a positive (efficiency improvement) or negative (costs, disruption) depending on future impacts.
• Currency and Hedging Volatility: Large swings in comprehensive income due to hedging and FX could cause volatility in reported results, possibly affecting investor sentiment.
• Investment Losses: Continued losses on equity investments could raise questions about non-core asset management, though they do not directly impact the company’s core healthcare business.

Summary for Investors

ResMed delivered another strong quarter, with robust revenue and profit growth, rising dividends, and a solid balance sheet. The company’s ongoing investment in R&D and restructuring signals a focus on future innovation and efficiency. However, investors should closely monitor the impact of restructuring, hedging losses, and equity investment performance on future results. The overall tone of the report is positive, with several factors (especially earnings growth and dividend increases) likely to be viewed favorably by the market.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full quarterly report and consult with their financial advisors before making investment decisions. All data is as disclosed by ResMed Inc. in its official filings for the period ended March 31, 2026.

View RESMED INC Historical chart here